FeesSafety
Pluang+

Saia reports Q3 2026 record revenue, EPS rise, and $250M stock buyback plan

Company Fundamentals
29 Oct 2026, 14:30 WIB
GlobeNewsWire
View Source
Bullish
Saia reports Q3 2026 record revenue, EPS rise, and $250M stock buyback plan

Saia, Inc. reported a record $982.5 million revenue for Q3 2026, up 17% from last year, with diluted EPS rising to $3.41. The company saw growth in LTL tonnage and shipments, reflecting strong pricing and operational improvements. Saia's Board authorized a $250 million stock repurchase program to enhance shareholder value. The company continues investing in its network and technology to support long-term growth and profitability.

Saia's third quarter 2026 results provide context for readers, with Pluang's Industrials sector data as of Oct 29, 2026 17:53 WIB showing that out of 135 priced US Industrials stocks, 76 rose and 57 fell. Notable movers include Caterpillar Inc (CAT) at USD 649.18 with a 1-day change of -9.00%, Howmet Aerospace Inc (HWM) at USD 210.48 up 7.76% and FTAI Aviation Ltd (FTAI) at USD 180.00 up 7.69%. The most notable figure is CAT's 9.00% decline on the day.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
1 hour ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
1 hour ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
2 hours ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
2 hours ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App